-transparent.png){kind=logo}
[11,12-3H2]Prostaglandin E3 was administered subcutaneously into male Sprague-Dawley rats in doses of 0.4 microgram-10 mg/kg body weight. 40-60% of the administered radioactivity was excreted in the urine. The major metabolite was isolated by solid phase extraction followed by three steps of high-performance liquid chromatography. The structure of the major metabolite (5-11% of the administered radioactivity) was 7 alpha,11 alpha-dihydroxy-5-ketotetranorprosta-9,13-dienoic acid as shown by gas-liquid chromatography-mass spectrometry and by its conversion into 11 alpha-hydroxy-5-ketotetranorprosta-4(8),9, 13-trienoic acid.
Related Publications
U Diczfalusy, and
M Hamberg
August 2005,
Clinical cancer research : an official journal of the American Association for Cancer Research,
U Diczfalusy, and
M Hamberg
May 1982,
Biochimica et biophysica acta,
U Diczfalusy, and
M Hamberg
August 1996,
The Journal of biological chemistry,
U Diczfalusy, and
M Hamberg
February 1974,
Life sciences,
U Diczfalusy, and
M Hamberg
August 2009,
Tetrahedron,
U Diczfalusy, and
M Hamberg
January 1994,
Drug metabolism and disposition: the biological fate of chemicals,
U Diczfalusy, and
M Hamberg
January 1992,
Drug metabolism and disposition: the biological fate of chemicals,
U Diczfalusy, and
M Hamberg
April 1969,
Journal of the American Chemical Society,
U Diczfalusy, and
M Hamberg
January 1976,
Drug metabolism and disposition: the biological fate of chemicals,
U Diczfalusy, and
M Hamberg
January 1977,
Toxicology and applied pharmacology,
